Atcor Medical Holdings Limited (ASX:ACG) has signed three new contracts worth circa $800,00 to supply its SphygmoCor systems and clinical trial support services.
AtCor develops and markets products for the early detection of target organ damage and management of cardiovascular and renal diseases.
Its SphygmoCor technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity.
The new deals are with major international pharmaceutical companies.
The clinical trials, for two existing clients and one new client, will be conducted in the U.S., Europe and Japan and run for 12-17 months.
Two studies are Phase II trials which if successful are expected to open a larger opportunity for AtCor when the trials progress to Phase III.
These include a trial in the acute coronary syndrome field, which is a condition brought on by the sudden reduction of blood to the heart, and a trial in the heart failure field.
Heart failure is a chronic and increasingly costly disease, and a growing focus for AtCor’s SphygmoCor technology in the clinic.
SphygmoCor has been specified for additional heart failure trials in FY2018 with other companies, and negotiations are underway.
SphygmoCor has also recently been used in drug trials for inflammatory disorders and type 2 diabetes, further expanding the company’s addressable market.